Cancer Research
Page 1 • 12 itemsGain critical insights into global cancer research trends, drug development pipelines, and clinical trial advancements for strategic pharma investment.
Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026
Alpha Tau reports 100% local disease control with Alpha DaRT in pancreatic cancer trials, showing favorable safety profile in 26 patients at DDW 2026.
Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026
Alpha Tau reports 100% local disease control with Alpha DaRT device in heavily pre-treated pancreatic cancer patients with favorable safety profile.
Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial
Celcuity's VIKTORIA-1 Phase 3 trial shows clinically meaningful progression-free survival improvement with gedatolisib in PIK3CA mutant patients.
Mabwell 9MW2821 Cervical Cancer Data to Be Presented at ESMO GC 2026 Conference
Mabwell announces presentation of clinical trial data for 9MW2821, a novel Nectin-4 targeting ADC for cervical cancer treatment at ESMO GC 2026.
Relay Therapeutics Q1 2026 Earnings: Zovegalisib PI3Kα Inhibitor Updates Expected May 5
Relay Therapeutics announces Q1 2026 financial results May 5, featuring updates on zovegalisib, the first pan-mutant selective PI3Kα inhibitor for cancer treatment.
Tovecimig Shows 56% Reduction in Cancer Progression Risk in Biliary Tract Cancer Trial
Tovecimig bispecific antibody demonstrates statistically significant improvement in progression-free survival versus paclitaxel alone in Phase 2/3 trial.
Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment
Apollomics reports clinical progress for vebreltinib c-MET inhibitor, with over 600 patients dosed and Phase 2/3 IND submission planned for NSCLC combination therapy.
NCCN Adds Nuvation Bio's Taletrectinib (IBTROZI) to Cancer Treatment Guidelines for ROS1-Positive NSCLC with Brain Metastases
NCCN includes Nuvation Bio's taletrectinib as recommended treatment option for ROS1-positive non-small cell lung cancer patients with brain metastases.
Alpha Tau Receives FDA Approval to Expand Alpha DaRT Pancreatic Cancer Trial with Gemcitabine-Abraxane Combination
Alpha Tau's Alpha DaRT IMPACT trial expands to include gemcitabine-Abraxane chemotherapy combination for pancreatic cancer patients, increasing trial size to 40.
Phanes Therapeutics to Present Updated Spevatamig Phase 2 Results for Metastatic Pancreatic Cancer at ASCO 2026
Phanes Therapeutics will present updated Phase 2 clinical trial results of spevatamig (PT886) combined with chemotherapy for metastatic pancreatic cancer treatment.
NETRIS Pharma's NP137 Shows Promising Results in Pancreatic Cancer Phase 1b Trial Published in Nature
NETRIS Pharma's NP137 anti-netrin-1 antibody achieved 16.43 months median survival in locally advanced pancreatic cancer patients in Phase 1b trial.
Pfizer Presents LORBRENA and BRAFTOVI Cancer Trial Updates at ASCO 2026
Pfizer showcases oncology pipeline at ASCO 2026 with new LORBRENA data for ALK-positive lung cancer and BRAFTOVI results for BRAF-mutant colorectal cancer.